U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Taewoong Medical Co., Ltd. - Close Out Letter 9/18/15
  1. Compliance Actions and Activities

CLOSEOUT LETTER

Taewoong Medical Co., Ltd. Sep 18, 2015

Taewoong Medical Co., Ltd. - Close Out Letter 9/18/15


Taewoong Medical Co., Ltd.

  

Department of Health and Human Services' logoDepartment of Health and Human Services

 
 Food and Drug Administration
10903 New Hampshire Avenue
White Oak Building 66
Silver Spring, MD 20993

SEP 18 2015
 

Kyongmin Shin
CEO
TaeWoong Medical Co., Ltd.
14 Gojeong-ro
Wolgot-myeon
Gimpo-si
Gyeonggi-do
REPUBLIC OF KOREA

Dear Mr. Shin:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to the Warning Letter dated November 25, 2014. Based on the Agency's evaluation, it appears that your firm has addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,

/S/

Carl Fischer, Ph.D.
Director
Division of International Compliance Operations
Office of Compliance
Center for Devices and Radiological Health